Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-08-20
2009-11-17
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S381000, C435S320100, C435S325000, C435S069700, C536S023400, C536S023500, C514S04400A
Reexamination Certificate
active
07618943
ABSTRACT:
The present invention relates to fusion polypeptides, comprising at least two peptides. The invention further relates to the use of these fusion proteins in antivascular therapy of neoplastic diseases and to their use I the production of a drug for the treatment of neoplastic diseases.
REFERENCES:
patent: 7425328 (2008-09-01), Wang
patent: 2006/0088524 (2006-04-01), Morrissey et al.
patent: WO 03/035688 (2003-05-01), None
Arap et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model”,Science279:377-380 (1998).
Banner et al., “The Crystal Structure of the Complex of Blood Coagulation Factor VIIa with Soluble Tissue Factor”,Nature380:41-46 (1996).
Bhagwa et al., “CD13/APN is Activated by Angiogenic Signals and is Essential for Capillary Tube Formation”,Blood97(3):652-659 (2001).
Brooks et al., “Requirement of Vascular Integrin αvβ3for Angiogenesis”,Science264:569-571 (1994).
Brooks et al., “Integrin αvβ3Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels”,Cell79:1157-1164 (1994).
Brooks et al., “Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3”,Cell85:683-693 (1996).
Brooks et al., “Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity”,Cell, 92:391-400 (1998).
Burg et al., “NG2 Proteoglycan-Binding Peptides Target Tumor Neovasculature”,Cancer Research59:2869-2874 (1999).
Burrows et al., “Up-Regulation of Endoglin on Vascular Endothelial Cells in Human Solid Tumors: Implications for Diagnosis and Therapy”,Clinical Cancer Research1:1623-1634 (1995).
Carnemolla et al., “A Tumor-associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors”,The Journal of Cell Biology108:1139-1148 (1989).
Curnis et al., “Enhancement of Tumor Necrosis Factor α Antitumor Immunotherapeutic Properties by Targeted Delivery to Aminopeptidase N (CD13)”,Nature Biotechnology18:1185-1190 (2000).
Curnis et al., “Differential Binding of Drugs Containing the NGR Motif to CD13 Isoforms in Tumor Vessels, Epithelia, and Myeloid Cells”,Cancer Research62:867-874 (2002).
Dvorak et al., “Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors: Concentration in Tumor Blood Vessels”,J. Exp Med. 174:1275-1278 (1991).
Dvorak et al., “Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermability, and Angiogenesis”,American Journal of Pathology, 146(5):1029-1039 (1995).
Ellerby et al., “Anti-Cancer Activity of Targeted Pro-Apoptotic Peptides”,Nature Medicine, 5(9):1032-1038 (1999).
Folkman et al., “Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia”,Nature339:58-61 (1989).
Gottstein et al., “Generation and Characterization of Recombinant Vascular Targeting Agents from Hybridoma Cell Lines”,BioTechniques30(1):190-199 (2001).
Healy et al., “Peptide Ligands for Integrn αvβ3Selected from Random Phage Display Libraries”,Biochemistry34:3948-3955 (1995).
Hu et al., “Comparison of Three Different Targeted Tissue Factor Fusion Proteins for Inducing Tumor Vessel Thrombosis”,Cancer Research63:5046-5053 (2003).
Huang et al., “Tumor Infarction in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature”,Science275:547-550 (1997).
Koivunen et al., “Selection of Peptides Binding to the α5β1Integrin from Phage Display Library”,The Journal of Biological Chemistry, 268(27):20205-20210 (1993).
Koivunen et al., “Tumor Targeting with a Selective Gelatinase Inhibitor”,Nature Biotechnology17:768-774 (1999).
Liu et al., “Prostate-specific Membrane Antigen Directed Selective Thrombotic Infarction of Tumors”,Cancer Research62:5470-5475 (2002).
Maisonpierre et al., “Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts In Vivo Angiogenesis”,Science277:55-60 (1997).
Morrissey et at, “Quantitation of Activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selectively Deficient in Promoting Factor VII Activation”,Blood81(3):734-744 (1993).
Nilsson et al., “Targeted Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogenesis, Mediates the Infarction of Solid Tumors in Mice”,Cancer Research61:711-716 (2001).
Olsen et al., “Targeting the Tumor Vasculature: Inhibition of Tumor Growth by a Vascular Endothelial Growth Factor-Toxin Conjugate”,Int. J. Cancer73:865-870 (1997).
Pasqualini et al., “Aminopeptidase N Is a Receptor for Tumor-homing Peptides and a Target for Inhibiting Angiogenesis”,Cancer Research60:722-727 (2000).
Peters et al., “Expression of Tie2/Tek in Breast Tumour Vasculature Provides a New Marker for Evaluation of Tumour Angiogenesis”,British Journal of Cancer77(1):51-56 (1998).
Ran et al., “Infarction of Solid Hodgkin's Tumors in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vascularture”,Cancer Research58:4646-4653 (1998).
Rettig et al., “Identification of Endosialin, a Cell Surface Glycoprotein of Vascular Endothelial Cells in Human Cancer”,Proc. Natl. Acad. Sci. USA89:10832-10836 (1992).
Rippmann et al., “Fusion of the Tissue Factor Extracellular Domain to a Tumour Stromaspecific Single-Chain Fragment Variable Antibody Results in an Antigen-Specific Coagulation-Promoting Molecule”,Giochemical Journal349(3):805-812 (2000).
Ruf et al., “Phospholipid-independent and -dependent Interactions Required for Tissue Factor Receptor and Cofactor Function”,The Journal of Biological Chemistry, 266(4):2158-2166 (1991).
Ruoslahti, “Targeting Tumor Vasculature with Homing Peptides from Phage Display”,Seminars in Cancer Biology10:435-442 (2000).
Scholz et al., “Correlation of Drug Response in Patients and in the Clonogenic Assay with Solid Human Tumour Xenografts”,Eur J. Cancer26(8):901-905 (1990).
Schnürch et al., “Expression of tie-2, a Member of a Novel Family of Receptor Tyrosine Kinases, In the Endothelial Cell Lineage”,Development119:957-968 (1993).
Schrappe et al., “Correlation of Chondroitin Sulfate Proteoglycan Expression on Proliferating Brain Capillary Endothelial Cells with the Malignant Phenotype of Astroglial Cells”,Cancer Research51:4986-4993 (1991).
Senger et al., “Angiogenesis Promoted by Vascular Endothelial Growth Factor: Regulation Through α1β1and α2β1Integrins”,Proc. Natl. Acad. Sci. USA94:13612-13617 (1997).
Suri et al., “Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, During Embryonic Angiogenesis”,Cell87:1171-1180 (1996).
Terman et al., “Biological Properties of VEGF/VPF Receptors”,Cancer and Metastasis Reviews15:159-163 (1996).
Topp et al., “Recombinant Human Interleukin-4 Inhibits Growth of Soe Human Lung Tumor Cell Lines In Vitro and In Vivo”,Blood82(9):2837-2844 (1993).
Topp et al., “Recombinant Human Interleukin 4 Has Antiproliferative Activity on Human Tumor Cell Lines Derived from Epithelial and Nonepithelial Histologies”,Cancer Research55:2173-2176 (1995).
Yun et al., “Involvement of Integrin αvβ3in Cell Adhesion, Motility, and Liver Metastasis of Murine RAW117 Large Cell Lymphoma”,Cancer Research56:3103-3111 (1996).
Kessler et al. “Generation of Fusion Proteins for Selective Occlusion of Tumor Vessels,” Current Drug Discovery Technologies, 5:1-8 (2008).
Bieker et al., “Infarction of tumor vessels by NGR-peptide directed targeting of tissue factor. Experimental results and first-in-man experience,” p
Berdel Wolfgang E.
Mesters Rolf M.
Allen Marianne P
Arnold & Porter LLP
Oncoscience AG
LandOfFree
Fusion polypeptides, and use thereof in antivascular tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion polypeptides, and use thereof in antivascular tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion polypeptides, and use thereof in antivascular tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4086742